AMGEN INC Files SEC form 10-Q, Quarterly Report

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Forward-looking statementsThis report and other documents we file with the U.S. Securities and Exch...

Could Celgene Beat the Biotech Slide?

Last Thursday, Celgene‘s (NASDAQ: CELG  ) first quarter earnings call left the market with mixed emotions. Adjusted earnings per share of $ 1.67 beat estimates by just $ 0.02. Revenue grew 18.5...